Clinical trial
Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for…
NCT00405938 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00405938 |
|---|---|
| Title | Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer |
| Official title | A Phase II Trial of Open-Label Bevacizumab Administered With Anastrozole or Fulvestrant as First-Line Therapy in Postmenopausal Hormone Receptor- Positive Metastatic Breast Cancer (With Trastuzumab in HER2-Positive Patients) |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Genentech, Inc. Industry AstraZeneca |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Bevacizumab, Anastrozole, Fulvestrant |
| Enrollment | 79 |
| Start date | Nov 1, 2006 |
| Primary completion | Jun 1, 2010 |
| Completion | Jun 1, 2011 |
| First posted | Nov 30, 2006 |
| Last update posted | Nov 18, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: